Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 8/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | DNM1L | O00429 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236823 | 0.89 | RAB9A (0.41) | CA9CA12NPC1RAB9AHTR2B | |
| SCHEMBL16236813 | 0.85 | HTR2B (0.49) | NPC1RAB9AHTR2BLMNAMAPT | |
| SCHEMBL18407885 | 0.85 | MEN1 (0.50) | CA9CA2CA1CA12HTR2B | |
| SCHEMBL16237797 | 0.79 | HTR2B (0.67) | HTR2BLMNAMAPT | |
| SCHEMBL21727482 | 0.78 | HTR2B (0.42) | HTR2BLMNAMAPT | |
| SCHEMBL18407955 | 0.75 | POLB (0.48) | CA9CA2CA1NPC1RAB9A | |
| SCHEMBL23677295 | 0.75 | TP53 (0.56) | CA9CA2CA1CA12LMNA | |
| SCHEMBL25091647 | 0.74 | NPC1 (0.41) | NPC1RAB9ALMNAMAPT | |
| SCHEMBL20131076 | 0.74 | LMNA (0.52) | CA9CA2CA1CA12LMNA | |
| SCHEMBL21727502 | 0.74 | THRB (0.47) | CA9CA2CA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121164-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-02-19 | — | — | EP | disclosed |